The therapeutic effect of anti-CD19 antibody on DHEA-induced PCOS mice

• DOI: 10.1016/j.intimp.2024.111711
• Publication Date: 2024-02-29T18:10:35Z
• Authors: Ting Wang; Xingliang Xiong; Na Xiao; Yizhong Yan; Xiaoyang Liu; Qi Xie; Xian Su; Maosheng Chen; Jing Peng; Siqi Wang; Hua Mei; Ge Lin; Fei Gong; Lamei Cheng
• Keywords: Mice; Ovarian Follicle; Tumor Necrosis Factor-alpha; Animals; Humans; Female; Dehydroepiandrosterone; Polycystic Ovary Syndrome; Adaptor Proteins, Signal Transducing

Immune dysregulation has been summarized as a critical factor in the occurrence and development of Polycystic ovary syndrome (PCOS), but potential mediators and mechanisms remain unclear. Our previous study showed that CD19+ B cells were involved in the pathogenesis of dehydroepiandrosterone (DHEA)-induced PCOS mice. Here, we studied the therapeutic potential of anti-CD19 antibody (aCD19 Ab) on DHEA-induced PCOS mice. The results showed that aCD19 Ab treatment improved ovarian pathological structure and function of PCOS mice, manifested by an increased number of corpus luteum, a decreased number of cystic follicles and atretic follicles, and regular estrus cycles. The aCD19 Ab treatment reduced the proportion of splenic CD21+ CD23low marginal zone B cells as well as the level of serum IgM and decreased the percentage of peripheral blood and splenic neutrophils. In particular, aCD19 Ab treatment reduced the apoptosis of granulosa cells and macrophage infiltration in ovarian secondary follicles of PCOS mice, as well as the expression of TNF-α in ovarian tissue and serum TNF-α levels. Moreover, we confirmed that TNF-α induced the apoptosis of human ovarian granulosa tumor cell line cells in vitro. Thus, our work demonstrates that aCD19 Ab treatment improves ovarian pathological phenotype and function by reducing local and systemic inflammation in PCOS mice, which may provide a novel insight into PCOS therapy.